Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 6Myeloproliferative Disorders 5Glioma 5Cholangiocarcinoma 5Leukemia 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Hematologic Neoplasms 2Ependymoma 2Chondrosarcoma 2Biliary Tract Neoplasms 2Xanthogranuloma, Juvenile 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Unknown Primary 1Neoplasm, Residual 1Lymphoma, Follicular 1IDH1-Mutated Malignancies 1

Interventions

Gemcitabine 92Cisplatin 70Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13Bevacizumab 13lenvatinib 12tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × ivosidenib × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Peking Union Medical College Hospital

Phase 2 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡